Semax

Overview

Semax is a synthetic neuropeptide derived from a fragment of the hormone ACTH, specifically the ACTH(4-10) sequence, modified for stability. It was developed in Russia and is used there as a medicine, primarily in the areas of neurology and cognition.

In Russia and some neighboring countries, semax is approved and used clinically for indications such as supporting recovery after ischemic stroke and for certain cognitive and neurological conditions. It is typically administered as a nasal solution, which allows it to reach the central nervous system relatively directly.

Outside that region, the situation is very different. Semax is not approved by the FDA or by European regulators, and in those markets it circulates as an unapproved nootropic or research chemical. This contrast — an established, approved drug in one regulatory system but unregulated elsewhere — is central to understanding its status, and consumers abroad are effectively using a product that has not been vetted by their own authorities.

How it works

Semax is thought to act on the central nervous system through several pathways. One prominent proposed mechanism involves increasing levels of brain-derived neurotrophic factor (BDNF), a protein that supports the survival, growth, and plasticity of neurons. Effects on related neurotrophic signaling have also been described.

Because it is derived from an ACTH fragment but modified to remove hormonal activity, semax is described as having neuromodulatory and neuroprotective properties without the classic hormonal effects of full ACTH. Researchers have linked it to influences on neurotransmitter systems and to protection of neural tissue under stress, which underlies its use in stroke recovery contexts.

It is also studied for effects on attention, memory, and stress adaptation, which is why it is marketed elsewhere as a nootropic. As with many peptides, the proposed mechanisms are supported largely by preclinical work and regional clinical use, and the precise pathways and their relevance to broad cognitive enhancement in healthy people remain incompletely defined.

Research & evidence

The research base for semax is concentrated in Russian studies, where it has been investigated and used clinically, most notably in the setting of ischemic stroke and certain other neurological and cognitive conditions. This regional clinical experience is the foundation for its approval there.

However, much of this evidence has not been widely replicated or validated in large international trials conducted to contemporary standards. Studies are often smaller or less accessible to the global research community, which makes it difficult for regulators elsewhere to fully evaluate its efficacy and safety.

For the popular nootropic claims — improved focus, memory, and resilience to stress in healthy individuals — the supporting evidence is weaker still and largely extrapolated from clinical or preclinical work rather than confirmed in robust trials of cognitive enhancement. The honest summary is that semax has real clinical use and research history in one region, but lacks the independent, high-quality validation that would justify the broad enhancement claims often made for it elsewhere.

Safety & legal status

In its approved Russian use, semax has generally been described as well tolerated, with relatively few reported side effects, in part because it is used as a nasal formulation and is modified to avoid hormonal activity. Even so, comprehensive long-term safety data meeting international standards are limited.

Because it acts on the central nervous system and neurotrophic signaling, its effects with prolonged or off-label use in healthy people are not well established, and unsupervised use carries the usual uncertainties of an unstudied long-term regimen.

Legally, semax is approved in Russia and some nearby countries but is not approved by the FDA or EU regulators, where it is sold as an unapproved nootropic or research chemical. Products purchased through these channels are not manufactured to pharmaceutical quality standards, so purity and dosing accuracy cannot be guaranteed. Anyone considering semax outside its approved markets should understand they are using an unregulated substance and should seek qualified medical advice rather than self-treating.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an analogue of ACTH(4-10), increases brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006. Peer-reviewed study
2. Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of semax in the acute period of hemispheric ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 1997. Peer-reviewed study
3. Gusev EI, Skvortsova VI, Chukanova EI. Semax in prevention of disease progression in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 2005. Peer-reviewed study
4. Liu R, Chen Y, Huang H, et al. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. Br J Pharmacol. 2025. Peer-reviewed study
5. Sciacca MFM, Naletova I, Giuffrida ML, et al. Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models. ACS Chem Neurosci. 2022. Peer-reviewed study
6. Glazova NY, Manchenko DM, Volodina MA, et al. Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. Neuropeptides. 2021. Peer-reviewed study